Construction of an immune-related ceRNA network to screen for potential diagnostic markers for autism spectrum disorder
Authors:
Open Access
- 17 November 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 1025813
Abstract
Purpose: The diagnosis of autism spectrum disorder (ASD) is reliant on evaluation of patients’ behavior. We screened the potential diagnostic and therapeutic targets of ASD through bioinformatics analysis.Methods: Four ASD-related datasets were downloaded from the Gene Expression Omnibus database. The “limma” package was employed to analyze differentially expressed messenger (m)RNAs, long non-coding (lnc)RNAs, and micro (mi)RNAs between ASD patients and healthy volunteers (HVs). We constructed a competing endogenous-RNA (ceRNA) network. Enrichment analyses of key genes were undertaken using the Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes database. The ImmucellAI database was used to analyze differences in immune-cell infiltration (ICI) in ASD and HV samples. Synthetic analyses of the ceRNA network and ICI was done to obtain a diagnostic model using LASSO regression analysis. Analyses of receiver operating characteristic (ROC) curves were done for model verification.Results: The ceRNA network comprised 49 lncRNAs, 30 miRNAs, and 236 mRNAs. mRNAs were associated with 41 cellular components, 208 biological processes, 39 molecular functions, and 35 regulatory signaling pathways. Significant differences in the abundance of 10 immune-cell species between ASD patients and HVs were noted. Using the ceRNA network and ICI results, we constructed a diagnostic model comprising five immune cell-associated genes: adenosine triphosphate-binding cassette transporter A1 (ABCA1), DiGeorge syndrome critical region 2 (DGCR2), glucose-fructose oxidoreductase structural domain gene 1 (GFOD1), glutaredoxin (GLRX), and SEC16 homolog A (SEC16A). The diagnostic performance of our model was revealed by an area under the ROC curve of 0.923. Model verification was done using the validation dataset and serum samples of patients.Conclusion:ABCA1, DGCR2, GFOD1, GLRX, and SEC16A could be diagnostic biomarkers and therapeutic targets for ASD.Keywords
This publication has 55 references indexed in Scilit:
- Brain Transcriptional and Epigenetic Associations with AutismPLOS ONE, 2012
- Aberrant Expression of Long Noncoding RNAs in Autistic BrainJournal of Molecular Neuroscience, 2012
- Genome-wide expression assay comparison across frozen and fixed postmortem brain tissue samplesBMC Genomics, 2011
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- Altered T cell responses in children with autismBrain, Behavior, and Immunity, 2011
- Glutathione pathway gene variation and risk of autism spectrum disordersJournal of Neurodevelopmental Disorders, 2011
- Sec16A defines the site for vesicle budding from the endoplasmic reticulum on exit from mitosisJournal of Cell Science, 2010
- Differential monocyte responses to TLR ligands in children with autism spectrum disordersBrain, Behavior, and Immunity, 2010
- Altered gene expression and function of peripheral blood natural killer cells in children with autismBrain, Behavior, and Immunity, 2009
- Genome‐wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associationsAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008